Profile: Endo International PLC (ENDP.OQ)
18 Jan 2017
Endo International plc, incorporated on October 31, 2013, is a global specialty pharmaceutical company focused on developing, manufacturing, marketing and distributing branded and generic pharmaceutical products, as well as over-the-counter medications through its operating companies- Endo Pharmaceuticals, Par Pharmaceutical, Paladin Labs and SOMAR. The Company’s segments include U.S. Branded Pharmaceuticals, which offer portfolio of branded pharmaceuticals such as Lidoderm, OPANA ER, Voltaren Gel, Percocet, BELBUCA, Fortesta Gel, Testim, Aveed, Supprelin LA, and XIAFLEX; U.S. Generic Pharmaceuticals portfolio consists of tablets, capsules, powders, injectables, liquids, nasal sprays, ophthalmics and patches, and International Pharmaceuticals segment includes various specialty pharmaceutical products for the Canadian, Latin American, South African and world markets. It sells generic products primarily in the United States across multiple therapeutic categories.
U.S. Branded Pharmaceuticals
The Company's Lidoderm is a topical patch product containing lidocaine. The Company's Lidoderm is used for the relief of the pain associated with post-herpetic neuralgia, a condition thought to result after nerve fibers are damaged during a case of Herpes Zoster. The Company's Opana ER is an opioid agonist indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. Opana ER represents the drug, in which oxymorphone is available in an oral, extended-release formulation and is available in approximately five milligram (mg), 7.5 mg, 10 mg, 15 mg, 20 mg, 30 mg and 40 mg tablets. The Company's Percocet is for the treatment of moderate to moderately severe pain. The Company's Voltaren Gel is a topical prescription treatment for the relief of joint pain of osteoarthritis in the knees, ankles, feet, elbows, wrists and hands.
The Company's Supprelin LA is a 12-month hydrogel implant based on its hydrogel polymer technology that delivers histrelin acetate, a gonadotropin releasing hormone (GnRH) agonist and is indicated for the treatment of central precocious puberty (CPP) in children. Its XIAFLEX is used for the treatment of adult patients with Dupuytren's Contracture (DC) with an abnormal buildup of collagen in the fingers, which limits or disables hand function. It is also indicated for the treatment of adult men with Peyronie's Disease (PD) with a collagen plaque and a penile curvature deformity of 30 degrees or greater at the start of therapy. Its Fortesta Gel is a 2% testosterone transdermal gel and is a treatment for men suffering from hypogonadism, also known as low testosterone (Low-T). Its Testim is a topical gel indicated for testosterone replacement therapy (TRT) in conditions associated with a deficiency or absence of endogenous testosterone.
The Company's Frova is indicated for the acute treatment of migraine headaches in adults. Its Valstar is a sterile solution for intravesical instillation of valrubicin, a chemotherapeutic anthracycline derivative. Valstar is also indicated for intravesical therapy of bacillus Calmette-Guerin (BCG)-refractory carcinoma in situ (CIS) of the urinary bladder in patients, for whom immediate cystectomy would be associated with unacceptable morbidity or mortality. Its Vantas is a 12-month hydrogel implant based on the Company's hydrogel polymer technology that delivers histrelin acetate, a Gonadotropin-releasing hormone (GnRH) agonist, and is indicated for the palliative treatment of advanced prostate cancer. Sumavel DosePro is indicated for adults for the acute treatment of migraine, with or without aura, and the acute treatment of cluster headache. Sumavel DosePro is a needle-free injection that comes in two doses (4 mg and 6 mg) and is delivered subcutaneously to patients. The Company's Aveed is a long-acting testosterone undecanoate for injection for the treatment of Low-T. Aveed is dosed only five times per year after the first month of therapy. The Company's TESTOPEL is a long-acting implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone. Its BELBUCA is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
U.S. Generic Pharmaceuticals
The Company's generics portfolio has a range of dosage forms and delivery systems, including immediate and extended release oral solids (tablets, orally disintegrating tablets, capsules and powders), injectables, liquids, nasal sprays, ophthalmics (sterile pharmaceutical preparations administered for ocular conditions) and transdermal patches (medicated adhesive patches designed to deliver the drug through the skin). The Company sells generic products primarily in the United States across multiple therapeutic categories.
The Company's International Pharmaceuticals segment includes various specialty pharmaceutical products for the Canadian, Mexican, South African and world markets. Its Paladin business, which is based in Canada, has a portfolio of products serving therapeutic areas, including attention-deficit/hyperactivity disorder (ADHD), pain, women's health and oncology. Its Somar business, based in Mexico, develops, manufactures and markets generic, branded generic and over-the-counter products across various segments, including dermatology and anti-infectives. Its Litha business, based in South Africa, is a healthcare group providing services, products and solutions to public and private hospitals, pharmacies, general and specialist practitioners, as well as government healthcare programs.
The Company competes with Abbott Laboratories, Allergan plc, Purdue Pharma, L.P., Jazz Pharmaceuticals plc, Shire plc, Horizon Pharma plc, Mallinckrodt plc, Teva Pharmaceutical Industries, Mylan, Inc. and Impax Laboratories, Inc.
Endo International PLC
Minerva House, Simmonscourt Road